


I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Mail Stop Patent Application, Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 12th day of November, 2003.

By



(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Benchaoui, et al. :

APPLICATION NO.: To Be Assigned : Examiner:

FILING DATE: Herewith : Group Art Unit:

TITLE: METHOD OF TREATING PARASITIC :  
INFECTION

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 (b).

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

In compliance with 37 C.F.R. § 1.98(d) Applicants are not providing a copy of the references "since they were previously cited by and submitted to the Office in a prior application". This continuing application claims priority under 35 U.S.C. § 120 to U.S. Serial No. 09/823,364.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

**EXPRESS MAIL NO. EV271823558 US**

A prompt and favorable response is earnestly solicited.

Date: 11/12/03

Respectfully submitted,

Christine S. Lee

Christine S. Lee  
Attorney for Applicant(s)  
Reg. No. 42,788

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-2144

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10911B				SERIAL NO. To Be Assigned						
				APPLICANT Benchaoui, et al.										
				FILING DATE Herewith				GROUP To Be Assigned						
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	4	8	3	1	0	1	7	05/16/89	Egerton	514/30			
<b>FOREIGN PATENT DOCUMENTS</b>														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	4	1	5	9	4	4	7/21/94	International	C07H	19/01		
	EP	0	3	7	9	3	4	1	1/90	European	C07H	17/08		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
			Hayes, et al.; An Evaluation of Piperazine Citrate for Preventing Prenatal Infections with the Common Dog Ascarid (Toxocara Canis); J.A.V.M.A.; p. 565-567 (1955).											
			T. Michael Burke, et al.; Fenbendazole treatment of pregnant bitches to reduce prenatal and lactogenic infections of Toxocara canis and Ancylostoma caninum in pups; J.A.V.M.A.; p. 987-990 (1983).											
			M. Payne-Johnson, et al.; Efficacy of selamectin administered topically to pregnant and lactating female dogs in the treatment and prevention of adult roundworm (Toxocara canis) infections and flea (Ctenocephalides felis felis) infestations in the dams and their pups; Veterinary Parasitology; 91:347-358 (2000).											
			P.A. Payne, et al.; Strategic use of ivermectin during pregnancy to control Toxocara canis in greyhound puppies; Veterinary Parasitology 85:305-312 (1999).											
			C. Epe, et al; A study on the prevention of prenatal and galactogenic Toxocara canis infections in pups by treatment of Infected bitches with ivermectin or doramectin; Appl. Parasitol. 36:115-123 (1995).											
			S. Lloyd, et al., Prenatal and transmammary infections of toxocara canis in dogs: effect of benzimidazole-carbamate anthelmintics on various developmental stages of the parasite; J. Small Anim. Pract.; 24:763-768 (1983).											
			T. Schnieder, et al.; Investigations into the prevention of neonatal toxocara canis infections in puppies by application of doramectin to the bitch; J. Vet. Med. B. 43:35-43 (1996).											
EXAMINER			DATE CONSIDERED											
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. EV271823558 US

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99